Under construction – not a live service
Sign in
Not yet taking people in SwitzerlandNo phase

Effect of moving from high altitude to sea level on lung blood flow

Tests how a week at sea level changes lung blood flow in healthy high-altitude residents.

Plain-language title generated from the registry record
Registry title: Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H

Key facts

Where
Zurich, SwitzerlandSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT07804485, who can take part

Where in Switzerland

  • University Hospital of ZurichZurich, SwitzerlandNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Silvia Ulrich Somaini
Trial code
NCT07804485
Record updated
4 September 2026
Original description
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.Read full original descriptionShow less

Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.

Inclusion: Adults aged 18-80 years and of all genders; Permanent residence > 2600 m; healthy: no self-perceived cardiopulmonary disease limiting daily activities; written informed consent to participate in the study.

Exclusion: any self-perceived cardiopulmonary disease limiting daily activities; Age <18 years or >80 years; People who cannot follow the study investigations; Participant permanently living < 2600m; Participant who traveled and stayed overnight at altitudes <2000 m in the past 4 weeks.

ClinicalTrials.gov NCT07804485